[1] ULLRICH H,OLSCHEWSKI M,MVNZEL T,et al.Coronary in-stent restenosis:predictors and treatment[J].Dtsch Arztebl Int,2021,118(38):637-644.
[2] LAWTON J S,TAMIS-HOLLAND J E,BANGALORE S,et al.2021 ACC/AHA/SCAI Guideline for coronary artery revascularization[J].Circulation,2022,145(3):e18-e114.
[3] NEUMANN F J,SOUSA-UVA M,AHLSSON A,et al.2018 ESC/EACTS Guidelines on myocardial revascularization[J].Eur Heart J,2019,40(2):87-165.
[4] 中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.
[5] KUNTZ R E,BAIM D S.Defining coronary restenosis.Newer clinical and angiographic paradigms[J].Circulation,1993,88(3):1310-1323.
[6] ALRAIES M C,DARMOCH F,TUMMALA R,et al.Diagnosis and management challenges of in-stent restenosis in coronary arteries[J].World J Cardiol,2017,9(8):640.
[7] MEHRAN R,DANGAS G,ABIZAID A S,et al.Angiographic patterns of in-stent restenosis:classification and implications for long-term outcome[J].Circulation,1999,100(18):1872-1878.
[8] SHLOFMITZ E,IANTORNO M,WAKSMAN R.Restenosis of drug-eluting stents:a new classification system based on disease mechanism to guide treatment and state-of-the-art review[J].Circ Cardiovasc Interv,2019,12(8):e007023.
[9] CHUNG I-M O,GOLD H K,SCHWARTZ S M,et al.Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment[J].J Am Coll Cardiol,2002,40(12):2072-2081.
[10] WELT F G P,ROGERS C.Inflammation and restenosis in the stent era[J].Arterioscler Thromb Vasc Biol,2002,22(11):1769-1776.
[11] 张珂瑞,李勇.冠心病患者经皮冠状动脉介入术后支架内再狭窄危险因素的研究进展[J].医学综述,2022,28(1):105-111.
[12] NAKAZAWA G,OTSUKA F,NAKANO M,et al.The pathology of neoatherosclerosis in human coronary implants[J].J Am Coll Cardiol,2011,57(11):1314-1322.
[13] SAKAMOTO A,SATO Y,KAWAKAMI R,et al.Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents:current clinical approaches and challenges[J].Expert Rev Cardiovasc Ther,2021,19(9):801-816.
[14] CASSESE S,BYRNE R A,TADA T,et al.Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography[J].Heart,2014,100(2):153-159.
[15] HUANG X,WANG X,ZOU Y,et al.Impact of cigarette smoking and smoking cessation on stent changes as determined by optical coherence tomography after sirolimus stent implantation[J].Am J Cardiol,2017,120(8):1279-1284.
[16] TODA N,TODA H.Nitric oxide-mediated blood flow regulation as affected by smoking and nicotine[J].Eur J Pharmacol,2010,649(1-3):1-13.
[17] PRASAD A M,MORGAN D A,NUNO D W,et al.Calcium/calmodulin‐dependent kinase ii inhibition in smooth muscle reduces angiotensin ii-induced hypertension by controlling aortic remodeling and baroreceptor function[J].J Am Heart Assoc,2015,4(6):e001949.
[18] QIN S Y,ZHOU Y,JIANG H X,et al.The association of diabetes mellitus with clinical outcomes after coronary stenting:a meta-analysis[J].PLoS One,2013,8(9):e72710.
[19] JAKUBIAK G K,PAWLAS N,CIELAR G,et al.Pathogenesis and clinical significance of in-stent restenosis in patients with diabetes[J].Int J Environ Res Public Health,2021,18(22):11970.
[20] THIRUVOIPATI T.Peripheral artery disease in patients with diabetes:epidemiology,mechanisms,and outcomes[J].World J Diabetes,2015,6(7):961.
[21] PRASAD K,TIWARI S.Therapeutic interventions for advanced glycation-end products and its receptor-mediated cardiovascular disease[J].Curr Pharm Des,2017,23(6):937-943.
[22] JACOBSON T A,ITO M K,MAKI K C,et al.National lipid association recommendations for patient-centered management of dyslipidemia:part 1—full report[J].J Clin Lipidol,2015,9(2):129-169.
[23] JANG J Y,KIM J S,SHIN D H,et al.Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation:qualitative optical coherence tomographic analysis[J].Atherosclerosis,2015,242(2):553-559.
[24] CAI Q,MUKKU V,AHMAD M.Coronary artery disease in patients with chronic kidney disease:a clinical update[J].Curr Cardiol Rev,2013,9(4):331-339.
[25] KASHIYAMA K,SONODA S,MURAOKA Y,et al.Coronary plaque progression of non-culprit lesions after culprit percutaneous coronary intervention in patients with moderate to advanced chronic kidney disease:intravascular ultrasound and integrated backscatter intravascular ultrasound study[J].Int J Cardiovasc Imaging,2015,31(5):935-945.
[26] KATO K,YONETSU T,JIA H,et al.Nonculprit coronary plaque characteristics of chronic kidney disease[J].Circ Cardiovasc Imaging,2013,6(3):448-456.
[27] LEE H F,CHENG Y W,PENG J R,et al.Impact of chronic kidney disease on long-term outcomes for coronary in-stent restenosis after drug-coated balloon angioplasty[J].J Cardiol,2021,78(6):564-570.
[28] MA G,ZHAO H,FEI Y,et al.Autoimmune diseases may increase adverse cardiovascular events after percutaneous coronary intervention:a systematic review and meta-analysis[J].Heart Lung Circ,2019,28(10):1510-1524.
[29] PEPE M,NAPOLI G,CARULLI E,et al.Autoimmune diseases in patients undergoing percutaneous coronary intervention:a risk factor for in-stent restenosis?[J].Atherosclerosis,2021,333:24-31.
[30] HU W,JIANG J.Hypersensitivity and in-stent restenosis in coronary stent materials[J].Front Bioeng Biotechnol,2022,10:1003322.
[31] KANSAKAR U,JANKAUSKAS S S,GAMBARDELLA J,et al.Targeting the phenotypic switch of vascular smooth muscle cells to tackle atherosclerosis[J].Atherosclerosis,2021,324:117-120.
[32] 蔡睿,王维铁.高通量生物信息学分析对经皮冠状动脉介入术后支架内再狭窄过程核心发病基因以及通路的预测[J].中国免疫学杂志,2021,37(16):2008-2011.
[33] ZHAO J,WANG X,WANG H,et al.Occurrence and predictive factors of restenosis in coronary heart disease patients underwent sirolimus-eluting stent implantation[J].Ir J Med Sci,2020,189(3):907-915.
[34] HASSAN A,DOHI T,MIYAUCHI K,et al.Prognostic impact of homocysteine levels and homocysteine thiolactonase activity on long-term clinical outcomes in patients undergoing percutaneous coronary intervention[J].J Cardiol,2017,69(6):830-835.
[35] 李奎,余丹.睡眠呼吸暂停低通气综合征对冠心病患者行经皮冠状动脉介入治疗的疗效影响[J].岭南心血管病杂志,2016,22(1):34-37.
[36] BEHAN M W,HOLM N R,DE BELDER A J,et al.Coronary bifurcation lesions treated with simple or complex stenting:5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study[J].Eur Heart J,2016,37(24):1923-1928.
[37] KOLANDAIVELU K,SWAMINATHAN R,GIBSON W J,et al.Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings[J].Circulation,2011,123(13):1400-1409.
[38] GÉNÉREUX P,MADHAVAN M V,MINTZ G S,et al.Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes[J].J Am Coll Cardiol,2014,63(18):1845-1854.
[39] LADISA J F,OLSON L E,DOUGLAS H A,et al.Alterations in regional vascular geometry produced by theoretical stent implantation influence distributions of wall shear stress:analysis of a curved coronary artery using 3D computational fluid dynamics modeling[J].Biomed Eng Online,2006,5(1):40.
[40] BYRNE R A,JONER M,KASTRATI A.Stent thrombosis and restenosis:what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014[J].Eur Heart J,2015,36(47):3320-3331.
[41] 吴轶喆,钱菊英,殷嘉晟,等.首例薄壁生物可吸收支架(BIOMAGIC)治疗冠状动脉原位病变3年造影和临床结果[J].中国介入心脏病学杂志,2022,30(9):711-713.
[42] GIUSTINO G,COLOMBO A,CAMAJ A,et al.Coronary in-stent restenosis[J].J Am Coll Cardiol,2022,80(4):348-372.
[43] LEE M S,JUREWITZ D,ARAGON J,et al.Stent fracture associated with drug-eluting stents:clinical characteristics and implications[J].Catheter Cardiovasc Interv,2007,69(3):387-394.
[44] ALFONSO F,BYRNE R A,RIVERO F,et al.Current treatment of in-stent restenosis[J].J Am Coll Cardiol,2014,63(24):2659-2673.
[45] DANGAS G D,CLAESSEN B E,CAIXETA A,et al.In-stent restenosis in the drug-eluting stent era[J].J Am Coll Cardiol,2010,56(23):1897-1907.
[46] HASSAN A K M,BERGHEANU S C,STIJNEN T,et al.Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis[J].Eur Heart J,2010,31(10):1172-1180.
[47] 关硕,林飞,赵国安.预测经皮冠状动脉介入术后支架内再狭窄的新型生物标志物[J].国际心血管病杂志,2021,48(5):261-264. |
